Latest Diagnostics News

Archer Materials has demonstrated electrical control in its quantum devices, marking a crucial step toward reliable qubit readout and scalable quantum chip manufacturing.

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

Cyclopharm Limited reaffirms its ambitious target of 250–300 US Technegas installations by late 2026, driven by FDA approval, CMS reimbursement, and a growing pipeline of healthcare sites. The company reports record half-year revenue growth, signaling strong momentum in the expanding lung imaging market.

Pro Medicus Limited’s U.S. arm has secured a significant five-year, A$44 million contract to deploy its cloud-based Visage 7 imaging platform with Advanced Radiology Management, marking a strategic expansion in North America.

Radiopharm Theranostics has reached the halfway mark in enrolling patients for its Phase 2b trial of RAD101, a novel imaging agent targeting brain metastases. Early data suggest RAD101 may outperform MRI in distinguishing tumor recurrence from radiation damage.

Genetic Signatures Limited unveiled a year of strategic transformation and robust financial growth at its 2025 AGM, highlighting leadership renewal and a sharpened commercial focus. The company’s FY25 revenue jumped 66%, driven by strong product demand and expanded market presence.

Proteomics International Laboratories has secured a $2.2 million Australian Government R&D tax rebate, reinforcing its financial position as it advances a promising pipeline of diagnostic tests based on its proprietary Promarker® technology.

Control Bionics has integrated Apple’s Brain-Computer Interface protocol into its NeuroNode products, promising simpler setup and enhanced communication for users with severe impairments.

Monash IVF Group has appointed Dr Victoria Atkinson as its new Managing Director and CEO, effective May 2026, signaling a strategic leadership shift for the assisted reproductive services provider.

Optiscan Imaging has entered a three-year strategic collaboration with Australian Clinical Labs to validate and deploy its InForm™ digital pathology platform, aiming to transform diagnostic workflows with real-time tissue analysis.

Archer Materials has partnered with CSIRO to develop cutting-edge quantum machine learning models aimed at revolutionizing fraud detection in financial transactions.

Integral Diagnostics has appointed Jason Martinez as its new CEO, set to lead the company’s growth and innovation efforts starting in 2026. Martinez brings over two decades of diagnostic imaging leadership experience, promising a strategic focus on expansion and operational excellence.